Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | JSKN033 |
| Synonyms | |
| Therapy Description |
JSKN033 is a combination of JSKN003, an antibody-drug conjugate (ADC) targeting ERBB2 (HER2), and KN035, a CD274 (PD-L1) inhibitor, which potentially induces antitumor activity (Journal for ImmunoTherapy of Cancer 2024;12). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| JSKN033 | JSKN-033|JSKN 033 | HER2 (ERBB2) Antibody 80 HER2 (ERBB2) Antibody-Drug Conjugate 36 PD-L1 Inhibitor 15 | JSKN033 is a combination of JSKN003, an antibody-drug conjugate (ADC) targeting ERBB2 (HER2), and KN035, a CD274 (PD-L1) inhibitor, which potentially induces antitumor activity (Journal for ImmunoTherapy of Cancer 2024;12). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06226766 | Phase Ib/II | JSKN033 | JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors | Terminated | AUS | 0 |